- Home
- NMG vs RIGL Comparison
NMG vs RIGL Comparison
Compare NMG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMG
- RIGL
- Stock Information
- Founded
- NMG 2011
- RIGL 1996
- Country
- NMG Canada
- RIGL United States
- Employees
- NMG N/A
- RIGL N/A
- Industry
- NMG Other Metals and Minerals
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- NMG Basic Materials
- RIGL Health Care
- Exchange
- NMG Nasdaq
- RIGL Nasdaq
- Market Cap
- NMG 172.2M
- RIGL 227.0M
- IPO Year
- NMG 2017
- RIGL 2000
- Fundamental
- Price
- NMG $1.43
- RIGL $13.32
- Analyst Decision
- NMG Strong Buy
- RIGL Buy
- Analyst Count
- NMG 1
- RIGL 4
- Target Price
- NMG $3.00
- RIGL $34.88
- AVG Volume (30 Days)
- NMG 34.6K
- RIGL 110.3K
- Earning Date
- NMG 08-14-2024
- RIGL 11-05-2024
- Dividend Yield
- NMG N/A
- RIGL N/A
- EPS Growth
- NMG N/A
- RIGL N/A
- EPS
- NMG N/A
- RIGL N/A
- Revenue
- NMG N/A
- RIGL $130,201,000.00
- Revenue This Year
- NMG N/A
- RIGL $38.26
- Revenue Next Year
- NMG N/A
- RIGL $24.21
- P/E Ratio
- NMG N/A
- RIGL N/A
- Revenue Growth
- NMG N/A
- RIGL 7.48
- 52 Week Low
- NMG $1.24
- RIGL $7.10
- 52 Week High
- NMG $3.21
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- NMG 33.98
- RIGL 61.38
- Support Level
- NMG $1.64
- RIGL $12.85
- Resistance Level
- NMG $1.64
- RIGL $13.47
- Average True Range (ATR)
- NMG 0.06
- RIGL 0.73
- MACD
- NMG -0.02
- RIGL -0.02
- Stochastic Oscillator
- NMG 0.00
- RIGL 70.83
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.